Advances in Cancer Research

Professor & Chairman, Dept of Cell & Molecular Pharmacology John C. West Chair of Cancer Research, Medical University of South Carolina, USAThe Tew laboratory maintains an interest in using redox pathways as a platform to develop therapeutic strategies through drug discovery/development and biomarker identification. We interrogate how reactive oxygen and nitrogen species (ROS/RNS) impact cancer cells and develop novel drugs that impact on glutathione based pathways. Our research efforts have been integral to studies that have identified glutathione S-transferases (GST) as important in drug resistance, catalytic detoxification and as arbiters of kinase-mediated cell signaling events. In addition, we have been instrumental in defining how GSTP contributes to the process by which cells respond to ROS by selective addition of glutathione to specific protein clusters, so called S-glutathionylation. Each of these research areas has had broad impact on a number of cancer disciplines. Moreover, we have also been seminally involved in the Phase I to III clinical testing of three oncology drugs, Telcyta, Telintra and NOV-002. Other ongoing translational efforts have produced two ongoing clinical trials to measure the effectiveness of serum S-glutathionylated serine proteinase inhibitors as possible biomarkers for exposure to hydrogen peroxide mouthwashes and radiation.

The AID dilemma: infection, or cancer?
The microRNA regulatory network in normal- and HTLV-1-transformed T cells
The multifaceted oncoprotein Tax: Sub-cellular localization, post-translational modifications and NF-?B activation
Lynch or not Lynch? Is that always a question?
Activation induced deaminase in antibody diversification and chromosome translocation
Opportunities and challenges in tumor angiogenesis research: back and forth between bench and bed
Molecular Logic Underlying Chromosomal Translocations, Random or non-Random?